A Cambridge biotech company using CRISPR gene editing to develop therapies for blood cancers said that its experimental treatment for acute myeloid leukemia proved safe in the first recipient, who is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback